Form 4: Angiodynamics CEO Receives Stock Grant
Insider Transaction (Form 4)
Eric Honroth, President and CEO and a Director of Angiodynamics Inc, reported multiple transactions in common stock on November 2, 2026.
Summary
- Grant/award: acquired 62,928 Common Stock on November 2, 2026; holds 62,928 after (Direct).
- Grant/award: acquired 38,265 Common Stock on November 2, 2026; holds 101,193 after (Direct).
- Grant/award: acquired 62,928 Performance Right on November 2, 2026; holds 62,928 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Eric Honroth — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-11-02 | Grant/award | Common Stock | 62,928 | — | — | 62,928 |
| 2026-11-02 | Grant/award | Common Stock | 38,265 | — | — | 101,193 |
| 2026-11-02 | Grant/award | Performance Right | 62,928 | — | — | 62,928 |
Key Dates
| Date | Description |
|---|---|
| 2026-11-02 | Grant/award (62,928 shares) |
| 2026-11-02 | Grant/award (38,265 shares) |
| 2026-11-02 | Grant/award (62,928 shares) |
Keywords
insider transaction, Form 4, ANGO, ANGIODYNAMICS INC, neutral, Eric Honroth
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.